Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT06311721 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT06311721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06311721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 9, 2024
Completion date
April 24, 2028
Enrollment
315 (actual)
Sites
218

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic non-squamous non-small cell lung cancer